Equifax Inc. shares are consolidating on Monday as they test a critical resistance level at $171. If the stock manages to break through this threshold, a significant upward move may follow. The $171 price point has historically served as a pivotal level for the Atlanta-based company, influencing investor behavior and price action over several months.

In February, Equifax shares experienced a steep decline that found a floor precisely at the $171 mark. This level attracted buying interest from investors who had previously sold near that price and sought to re-enter their positions. The accumulation of buy orders at this price created strong support in late March and again in April, preventing further downside.

However, the dynamic shifted in May when the stock broke below this established support. This breach led many investors who had purchased near $171 to hold onto losing positions with the intent of exiting at break-even. As Equifax has rallied back to this level, these remorseful buyers are now placing sell orders, transforming the former support into a resistance zone.

The following table outlines the key price action phases for Equifax at the $171 level:

Support and resistance levels are essential concepts in technical analysis, representing price zones where supply and demand imbalances typically cause reversals or breakouts. Traders monitor these levels closely to identify potential profit opportunities when trends change or key levels are breached.

Wells Fargo analyst Jason Haas has maintained an Overweight rating on Equifax (NYSE: EFX) while lowering the price target to $220 from $230. The adjustment reflects a revised outlook on the stock's valuation despite the continued positive stance.

Separately, UBS analyst Kevin McVeigh has maintained a Buy rating on Equifax and raised the price target to $215 from $212. This revised target indicates confidence in the company's future growth prospects and strong operational performance.

Equifax operates as a data analytics and technology company, providing insights and solutions to businesses and consumers. The conflicting price target adjustments highlight differing views on the stock's near-term trajectory, though both firms recommend buying the shares.

The following table summarizes the recent rating and price target changes from both firms:

Investors will be watching Equifax's upcoming earnings reports to see if the company meets the varied expectations set by these analysts.